Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations.
Jacek KubicaUrszula AdamskaMałgorzata OstrowskaEliano Pio NavareseJacek KubicaPublished in: Expert opinion on pharmacotherapy (2018)
Elderly ACS patients are characterized by simultaneously increased risk of cardiovascular events and bleeding. Very few studies assessing the efficacy and safety of novel ACS pharmacotherapy in geriatric patients are currently available. Guidelines on the treatment of ACS are based on the overall results of major randomized clinical trials (RCTs), and data supporting the recommended therapy in elderly mainly derive from subanalyses of these RCTs. Properly designed and powered RCTs are necessary to properly evaluate the net effect of current and emerging pharmacotherapy in geriatric patients. Until such data are available, elderly ACS patients should receive treatment according to the general recommendations.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- ejection fraction
- newly diagnosed
- cardiovascular events
- peritoneal dialysis
- type diabetes
- atrial fibrillation
- patient reported outcomes
- electronic health record
- percutaneous coronary intervention
- bone marrow
- middle aged
- smoking cessation
- clinical practice
- cell therapy